Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
World J Gastrointest Endosc ; 8(9): 391-4, 2016 May 10.
Article in English | MEDLINE | ID: mdl-27170840

ABSTRACT

Splenic rupture is a rare complication of diagnostic and therapeutic gastrointestinal endoscopy procedures. Herein, we report for the first time a case of splenic rupture following therapeutic retrograde double-balloon enteroscopy, which occurred in an 85-year-old man who was treated for recurrent mid-intestinal bleeding that resulted from ileal angioectasia. This patient promptly underwent an operation and eventually recovered.

2.
Hepatology ; 51(6): 2069-76, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20196120

ABSTRACT

UNLABELLED: The incidence of de novo development of esophageal varices (EV) in patients with compensated liver cirrhosis has been determined by few studies in the short term and never in the long term. The aims of the present study were to determine the incidence and the risk factors associated with the development of EV and to assess whether antiviral treatment and achievement of sustained virologic response (SVR) may prevent de novo EV development in patients with HCV-induced cirrhosis. We studied 218 patients with compensated EV-free, HCV-induced cirrhosis consecutively enrolled between 1989 and 1992 at three referral centers in Milan, Italy. Endoscopic surveillance was performed at 3-year intervals according to international guidelines. SVR was defined as undetectable serum HCV-RNA 24 weeks after treatment discontinuation. During a median follow-up of 11.4 years, 149/218 (68%) patients received antiviral treatment and 34 (22.8%) achieved SVR. None of the SVR patients developed EV compared with 22 (31.8%) of the 69 untreated subjects (P < 0.0001) and 45 (39.1%) of the 115 non-SVR patients (P < 0.0001). On multivariate analysis, HCV genotype 1b (hazard ratio [HR] 2.40; 95% confidence interval [CI] 1.17-4.90) and baseline model for end-stage liver disease (MELD) score (HR 1.20; 95% CI 1.07-1.35 for 1 point increase) were independent predictors of EV. CONCLUSION: In the long term, the achievement of SVR prevents the development of EV in patients with compensated HCV-induced cirrhosis. Therefore, in these patients, endoscopic surveillance can be safely delayed or avoided. Genotype 1b infection and MELD score identify the subset of patients at higher risk of EV development who need tailored endoscopic surveillance.


Subject(s)
Antiviral Agents/therapeutic use , Esophageal and Gastric Varices/prevention & control , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/complications , Aged , Carcinoma, Hepatocellular/epidemiology , Esophageal and Gastric Varices/epidemiology , Esophageal and Gastric Varices/etiology , Female , Follow-Up Studies , Humans , Incidence , Italy/epidemiology , Liver Cirrhosis/virology , Liver Neoplasms/epidemiology , Male , Middle Aged , Prospective Studies , Risk Factors
3.
J Hepatol ; 49(4): 564-71, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18706734

ABSTRACT

BACKGROUND/AIMS: Biochemical tests and ultrasonography (US) are useful in the non-invasive assessment of liver fibrosis in patients with chronic hepatitis C (CH-C); however histology remains the reference standard. This multicenter, cross-sectional cohort study evaluated the accuracy of APRI (AST-to-platelet-ratio-index) and liver surface ultrasound nodularity (LSN), singularly and sequentially combined in an algorithm, in diagnosing advanced fibrosis (i.e. METAVIR F3,F4), to derive a prediction rule to confirm or exclude F3,F4. METHODS: Four hundred and thirty consecutive CH-C patients with elevated ALT, grouped into a first cohort (training set), and an internal and an external validation cohort, were studied. APRI and LSN were compared to liver biopsy and sequentially combined in order to obtain a predictive rule for advanced fibrosis METAVIR F3,F4. RESULTS: LSN was negative and APRI < or = 1 in 185/430 patients, whereas LSN was positive and APRI>2 in 46/430 cases, with a 94% diagnostic accuracy for presence/absence of F3, F4, respectively. In a further 60/430 patients, F3,F4 was detected with an accuracy of 83%. In the remaining cases no classification was possible. CONCLUSIONS: An algorithm based on APRI and LSN confirms or excludes F3,F4 in 54% of CH-C patients with elevated ALT and suggests a highly probable diagnosis in a further one-sixth of patients, thus rendering liver biopsy unnecessary in these patients.


Subject(s)
Algorithms , Hepatitis C/blood , Hepatitis C/diagnostic imaging , Liver Cirrhosis/blood , Liver Cirrhosis/diagnostic imaging , Adult , Aged , Aspartate Aminotransferases/blood , Blood Platelets/pathology , Cohort Studies , Cross-Sectional Studies , Disease Progression , Female , Hepatitis C/complications , Humans , Liver/diagnostic imaging , Liver/pathology , Liver Cirrhosis/complications , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity , Severity of Illness Index , Ultrasonography
4.
Ann Hepatol ; 7(2): 114-9, 2008.
Article in English | MEDLINE | ID: mdl-18626427

ABSTRACT

Nowadays, hepatitis C infection has been identified as the main cause of chronic liver disease, including cirrhosis and hepatocellular carcinoma in Western Countries. However, despite its large diffusion (with more than 150 million of people infected world-wide), the lack of symptoms during the acute phase, together with the indolent course of the disease over time, hampers the difficulties to assess the natural history of the disease, which still remains an interesting clinical dilemma. This complexity can also be argued from the large heterogeneity of disease complication's rate observed when different methodological approaches were used (retrospective cohort studies, prospective cohort studies, retrospective-prospective cohort studies). Moreover, the progression of the disease could also be dramatically affected by many variables related to the host, the virus and the environment. Finally, in the last few years, the long-term outcome of the infected subjects, has been deeply modified by the use of efficacy antiviral therapy, as shown by the better survival observed in patients who had achieved a sustained virological response after interferon treatment.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/pathogenicity , Hepatitis C/drug therapy , Disease Progression , Hepatitis C/epidemiology , Humans , Prevalence
SELECTION OF CITATIONS
SEARCH DETAIL
...